TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.

2025年4月15日，星期二——輝瑞公司停止了一種每日一次的治療肥胖症藥物的開發，因爲一名臨牀試驗參與者顯示出可能的肝損傷跡象。

The company said the injury went away after the person stopped taking the drug, called danuglipron,

公司表示，該人士停止服用名爲danuglipron的藥物後，傷害消失了。

The Associated Press

美聯社

reported.

已報告。

The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.

據輝瑞公司發言人稱，該藥片正處於早期測試階段，以幫助確定最佳劑量。

The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).

公司原計劃將該藥物投入後期試驗，這通常是提交美國食品和藥物管理局 (FDA) 審查前的最後一步。

Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.

輝瑞將停止對丹納格列波隆的所有測試，包括其與其他藥物聯合用於肥胖症治療的測試。然而，該公司表示仍計劃繼續研究其他處於早期階段的肥胖症治療方法。

Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s

肥胖症藥物已經成爲製藥公司的主要關注點。像禮來公司（Eli Lilly）的可注射治療藥物等。

Zepbound

澤普綁定

and Novo Nordisk’s

諾和諾德的

Wegovy

韋哥維

have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone,

帶來了數十億美元的收入。僅2024年，Zepbound就賺了近50億美元，

The Associated Press

美聯社

reported.

據報道。

But these drugs must be injected, which some folks don't want to do.

但是這些藥物必須通過注射，有些人不想這樣做。

As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.

因此，製藥商一直在競相開發藥片版本。禮來公司預計將在今年發佈其正在研究的兩種口服減肥藥的新數據。

While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.

雖然對這些治療的需求很高，但獲取途徑一直是個問題。一些患者面臨保險問題或高昂的自付費用。

Even with recent price cuts, many of these medications still cost hundreds of dollars per month.

即使近期價格有所下調，許多此類藥物每月的費用仍高達數百美元。

Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.

輝瑞公司已於 2023 年底停止了每日兩次服用的丹那列普隆的測試，當時試驗中超過一半的人已停止服用該藥。

Whatever your topic of interest,

無論你感興趣的話題是什麼，

subscribe to our newsletters

訂閱我們的新聞通訊

to get the best of Drugs.com in your inbox.

獲取 Drugs.com 的最新資訊到您的郵箱。